比美替尼、恩考拉非尼与西妥昔单抗三药联合治疗BRAF V600E突变转移性结直肠癌:III期BEACON结直肠癌研究安全性导入期结果
BEACON III期研究安全性导入期纳入30例既往一或两线治疗失败的BRAF V600E突变转移性结直肠癌患者,接受恩考拉非尼300 mg每日一次、比美替尼45 mg每日两次联合标准每周西妥昔单抗。5例发生剂量限制性毒性,常见3/4级不良事件为疲乏(13%)等。29例可评估患者确认总缓解率48%(95%CI 29.4%至67.5%),中位无进展生存期8.0个月(95%CI 5.6至9.3个月),中位总生存期15.3个月(95%CI 9.6个月至未达到)。
要点
- 30例中5例发生剂量限制性毒性,包括浆液性视网膜病变2例、可逆性左心室射血分数降低1例、西妥昔单抗相关输液反应2例。
- 最常见3/4级不良事件为疲乏(13%)、贫血(10%)、肌酸磷酸激酶升高(10%)、AST升高(10%)和尿路感染(10%)。
- 29例BRAF V600E突变患者确认总缓解率48%(95%CI 29.4%至67.5%),中位无进展生存期8.0个月(95%CI 5.6至9.3个月),中位总生存期15.3个月(95%CI 9.6个月至未达到)。
核心结论
- 在安全性导入期中,恩考拉非尼、比美替尼与西妥昔单抗方案的安全性和耐受性可控,可接受以启动研究的随机部分。
- 观察到的疗效与现有治疗相比有前景,若在随机部分得到证实,该方案可能成为既往治疗过的BRAF V600E突变转移性结直肠癌的新标准治疗。
研究设计与样本
- 开放标签、随机、三臂III期BEACON结直肠癌研究(ClinicalTrials.gov注册号NCT02928224;欧盟临床试验注册号EudraCT2015-005805-35)的安全性导入期。
- 计划在随机部分启动前招募30例既往一或两线治疗失败的BRAF V600E突变转移性结直肠癌患者。
- 治疗方案为恩考拉非尼300 mg每日一次、比美替尼45 mg每日两次联合标准每周西妥昔单抗。
- 主要终点为安全性,包括剂量限制性毒性发生率;疗效终点包括总缓解率、无进展生存期和总生存期。
主要发现
- 30例接受治疗患者中5例发生剂量限制性毒性,包括浆液性视网膜病变2例、可逆性左心室射血分数降低1例、西妥昔单抗相关输液反应2例。
- 最常见3/4级不良事件为疲乏(13%)、贫血(10%)、肌酸磷酸激酶升高(10%)、AST升高(10%)和尿路感染(10%)。
- 29例BRAF V600E突变肿瘤患者(1例为非BRAF V600E突变肿瘤,未纳入疗效分析)确认总缓解率为48%(95%CI 29.4%至67.5%)。
- 29例患者中位无进展生存期为8.0个月(95%CI 5.6至9.3个月),中位总生存期为15.3个月(95%CI 9.6个月至未达到),中位随访时间18.2个月(范围16.6至19.8个月)。
关键数值与推荐
- 确认总缓解率48%(95%CI 29.4%至67.5%),中位无进展生存期8.0个月(95%CI 5.6至9.3个月),中位总生存期15.3个月(95%CI 9.6个月至未达到)。
- 剂量限制性毒性发生5例,包括浆液性视网膜病变2例、可逆性左心室射血分数降低1例、西妥昔单抗相关输液反应2例。
- 3/4级不良事件发生率:疲乏13%、贫血10%、肌酸磷酸激酶升高10%、AST升高10%、尿路感染10%。
临床怎么用
- 作者认为该方案的安全性和耐受性可控,可接受以启动研究的随机部分。
- 作者认为观察到的疗效与现有治疗相比有前景,若在随机部分得到证实,该方案可能成为既往治疗过的BRAF V600E突变转移性结直肠癌的新标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( ClinicalTrials.gov identifier: NCT02928224; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). PATIENTS AND METHODS: Before initiation of the randomized portion of the BEACON Colorectal Cancer trial, 30 patients with BRAF V600E-mutant mCRC who had experienced treatment failure with one or two prior regimens were to be recruited to a safety lead-in of encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab. The primary end point was safety, including the incidence of dose-limiting toxicities. Efficacy end points included overall response rate, progression-free survival, and overall survival. RESULTS: Among the 30 treated patients, dose-limiting toxicities occurred in five patients and included serous retinopathy (n = 2), reversible decreased left ventricular ejection fraction (n = 1), and cetuximab-related infusion reactions (n = 2). The most common grade 3 or 4 adverse events were fatigue (13%), anemia (10%), increased creatine phosphokinase (10%), increased AST (10%), and urinary tract infections (10%). In 29 patients with BRAF V600E-mutant tumors (one patient had a non-BRAF V600E-mutant tumor and was not included in the efficacy analysis), the confirmed overall response rate was 48% (95% CI, 29.4% to 67.5%), median progression-free survival was 8.0 months (95% CI, 5.6 to 9.3 months), and median overall survival was 15.3 months (95% CI, 9.6 months to not reached), with median duration of follow-up of 18.2 months (range, 16.6 to 19.8 months). CONCLUSION: In the safety lead-in, the safety and tolerability of the encorafenib, binimetinib, and cetuximab regimen is manageable and acceptable for initiation of the randomized portion of the study. The observed efficacy is promising compared with available therapies and, if confirmed in the randomized portion of the trial, could establish this regimen as a new standard of care for previously treated BRAF V600E-mutant mCRC.
引用
- Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. J Clin Oncol. 2019. PMID: 30892987. doi:10.1200/JCO.18.02459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。